MedSci临床研究设计评选,实验方案免费interview!

2013-05-27 MedSci MedSci原创

临床研究设计是优秀临床研究成果的第一个环节,为了进一步鼓励和支持国内临床科研工作者更好的设计并实施研究项目,MedSci特别开展临床研究设计方案评选大赛!上传您的临床研究设计方案,评审委员会将从课题可行性、新颖性和方案严谨性及临床指导意义等方面给出评审意见,同时优秀者将获得MedSci LEAP科研基金资助。MedSci通过本次甄选、点评及协助修改临床研究设计方案的方式,旨在帮助更多的中国临床工作

临床研究设计是优秀临床研究成果的第一个环节,为了进一步鼓励和支持国内临床科研工作者更好的设计并实施研究项目,MedSci特别开展临床研究设计方案评选大赛!

上传您的临床研究设计方案,评审委员会将从课题可行性、新颖性和方案严谨性及临床指导意义等方面给出评审意见,同时优秀者将获得MedSci LEAP科研基金资助。MedSci通过本次甄选、点评及协助修改临床研究设计方案的方式,旨在帮助更多的中国临床工作者完善临床研究方案,提升临床研究能力!
 
一、活动征集时间:2013年6月1日~2013年7月20日;
二、活动征集对象:所有中国籍临床工作者,年龄40周岁以内(含40周岁);
三、活动流程:
1、  参赛者在征集时间内,填写MedSci课题设计评选活动申请表发送至 Grant@medsci.cn
,或在线报名。
特别声明:报名成功后会有市场部专人与参赛者联系,参赛者须在7/20前将临床研究设计方案交至主办方。参赛者所有申请信息均适用于MedSci保密条例;
2、  MedSci学术委员会将从对所有征集方案进行初审,30个工作日内公布初审结果,初审结果敬请留意MedSci官方网站公告栏; 
3、  初审合格的设计方案将由MedSci LEAP科研基金委员会进行复审,15个工作日后将公布获奖名单。
四、奖项设置
1、  优胜奖(1名)    详细书面评审报告一份+30000元MedSci LEAP科研基金奖励
(需对公转账,用于资助得奖课题*。)
2、  优秀奖(3名)    详细书面评审报告一份+3000 MedSci科研积分奖励*
3、  参与奖           500 MedSci科研积分奖励+修改意见或免费interview
 
*优胜奖得奖者也可选择将30000元LEAP科研基金转换成MedSci等值科研积分,用于本课题后续统计及文章等相关服务
*MedSci科研积分可用于查阅文献、兑换服务、参加学术研讨会等。选择MedSci服务时,积分可抵现金使用,1积分=1元)

更多活动详情 请参阅https://www.medsci.cn/z/20130601/


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=6079, encodeId=5e4a60e9f2, content=<font color=red>目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。</font> <br> ------------------------------- <br> xingxing7021于2013-8-23 16:05:00 评论道: <br> 结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=管理员, createdTime=Sat Aug 24 14:11:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6077, encodeId=175f60e778, content=结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xingxing7021, createdTime=Fri Aug 23 16:05:00 CST 2013, time=2013-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5931, encodeId=9b4a5931b1, content=很好,鼓励积极参与。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=377584482, createdName=hong0hui, createdTime=Wed Jul 17 20:59:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5748, encodeId=66cf5e4822, content=值得参加, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=88gogo, createdTime=Thu May 30 16:13:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585662, encodeId=e4ac1585662a5, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605966, encodeId=33dd16059668f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5742, encodeId=f4815e42c0, content=很好的活动,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.173.34.157, createdTime=Mon May 27 17:49:00 CST 2013, time=2013-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5741, encodeId=5f515e41a0, content=顶一个~努力赚积分!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211213/a4233b110a314856b51b2ba7363cc1a1/02edceab314e4237aec74a0678eee6bf.jpg, createdBy=507370304, createdName=ellen0820, createdTime=Mon May 27 17:13:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2013-08-24 管理员

    目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。
    -------------------------------
    xingxing7021于2013-8-23 16:05:00 评论道:
    结果在啥地方公告、?有谁看到自己申请到了吗?

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=6079, encodeId=5e4a60e9f2, content=<font color=red>目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。</font> <br> ------------------------------- <br> xingxing7021于2013-8-23 16:05:00 评论道: <br> 结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=管理员, createdTime=Sat Aug 24 14:11:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6077, encodeId=175f60e778, content=结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xingxing7021, createdTime=Fri Aug 23 16:05:00 CST 2013, time=2013-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5931, encodeId=9b4a5931b1, content=很好,鼓励积极参与。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=377584482, createdName=hong0hui, createdTime=Wed Jul 17 20:59:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5748, encodeId=66cf5e4822, content=值得参加, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=88gogo, createdTime=Thu May 30 16:13:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585662, encodeId=e4ac1585662a5, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605966, encodeId=33dd16059668f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5742, encodeId=f4815e42c0, content=很好的活动,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.173.34.157, createdTime=Mon May 27 17:49:00 CST 2013, time=2013-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5741, encodeId=5f515e41a0, content=顶一个~努力赚积分!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211213/a4233b110a314856b51b2ba7363cc1a1/02edceab314e4237aec74a0678eee6bf.jpg, createdBy=507370304, createdName=ellen0820, createdTime=Mon May 27 17:13:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2013-08-23 xingxing7021

    结果在啥地方公告、?有谁看到自己申请到了吗?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=6079, encodeId=5e4a60e9f2, content=<font color=red>目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。</font> <br> ------------------------------- <br> xingxing7021于2013-8-23 16:05:00 评论道: <br> 结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=管理员, createdTime=Sat Aug 24 14:11:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6077, encodeId=175f60e778, content=结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xingxing7021, createdTime=Fri Aug 23 16:05:00 CST 2013, time=2013-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5931, encodeId=9b4a5931b1, content=很好,鼓励积极参与。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=377584482, createdName=hong0hui, createdTime=Wed Jul 17 20:59:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5748, encodeId=66cf5e4822, content=值得参加, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=88gogo, createdTime=Thu May 30 16:13:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585662, encodeId=e4ac1585662a5, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605966, encodeId=33dd16059668f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5742, encodeId=f4815e42c0, content=很好的活动,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.173.34.157, createdTime=Mon May 27 17:49:00 CST 2013, time=2013-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5741, encodeId=5f515e41a0, content=顶一个~努力赚积分!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211213/a4233b110a314856b51b2ba7363cc1a1/02edceab314e4237aec74a0678eee6bf.jpg, createdBy=507370304, createdName=ellen0820, createdTime=Mon May 27 17:13:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2013-07-17 hong0hui

    很好,鼓励积极参与。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=6079, encodeId=5e4a60e9f2, content=<font color=red>目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。</font> <br> ------------------------------- <br> xingxing7021于2013-8-23 16:05:00 评论道: <br> 结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=管理员, createdTime=Sat Aug 24 14:11:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6077, encodeId=175f60e778, content=结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xingxing7021, createdTime=Fri Aug 23 16:05:00 CST 2013, time=2013-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5931, encodeId=9b4a5931b1, content=很好,鼓励积极参与。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=377584482, createdName=hong0hui, createdTime=Wed Jul 17 20:59:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5748, encodeId=66cf5e4822, content=值得参加, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=88gogo, createdTime=Thu May 30 16:13:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585662, encodeId=e4ac1585662a5, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605966, encodeId=33dd16059668f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5742, encodeId=f4815e42c0, content=很好的活动,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.173.34.157, createdTime=Mon May 27 17:49:00 CST 2013, time=2013-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5741, encodeId=5f515e41a0, content=顶一个~努力赚积分!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211213/a4233b110a314856b51b2ba7363cc1a1/02edceab314e4237aec74a0678eee6bf.jpg, createdBy=507370304, createdName=ellen0820, createdTime=Mon May 27 17:13:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2013-05-30 88gogo

    值得参加

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=6079, encodeId=5e4a60e9f2, content=<font color=red>目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。</font> <br> ------------------------------- <br> xingxing7021于2013-8-23 16:05:00 评论道: <br> 结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=管理员, createdTime=Sat Aug 24 14:11:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6077, encodeId=175f60e778, content=结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xingxing7021, createdTime=Fri Aug 23 16:05:00 CST 2013, time=2013-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5931, encodeId=9b4a5931b1, content=很好,鼓励积极参与。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=377584482, createdName=hong0hui, createdTime=Wed Jul 17 20:59:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5748, encodeId=66cf5e4822, content=值得参加, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=88gogo, createdTime=Thu May 30 16:13:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585662, encodeId=e4ac1585662a5, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605966, encodeId=33dd16059668f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5742, encodeId=f4815e42c0, content=很好的活动,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.173.34.157, createdTime=Mon May 27 17:49:00 CST 2013, time=2013-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5741, encodeId=5f515e41a0, content=顶一个~努力赚积分!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211213/a4233b110a314856b51b2ba7363cc1a1/02edceab314e4237aec74a0678eee6bf.jpg, createdBy=507370304, createdName=ellen0820, createdTime=Mon May 27 17:13:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=6079, encodeId=5e4a60e9f2, content=<font color=red>目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。</font> <br> ------------------------------- <br> xingxing7021于2013-8-23 16:05:00 评论道: <br> 结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=管理员, createdTime=Sat Aug 24 14:11:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6077, encodeId=175f60e778, content=结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xingxing7021, createdTime=Fri Aug 23 16:05:00 CST 2013, time=2013-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5931, encodeId=9b4a5931b1, content=很好,鼓励积极参与。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=377584482, createdName=hong0hui, createdTime=Wed Jul 17 20:59:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5748, encodeId=66cf5e4822, content=值得参加, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=88gogo, createdTime=Thu May 30 16:13:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585662, encodeId=e4ac1585662a5, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605966, encodeId=33dd16059668f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5742, encodeId=f4815e42c0, content=很好的活动,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.173.34.157, createdTime=Mon May 27 17:49:00 CST 2013, time=2013-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5741, encodeId=5f515e41a0, content=顶一个~努力赚积分!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211213/a4233b110a314856b51b2ba7363cc1a1/02edceab314e4237aec74a0678eee6bf.jpg, createdBy=507370304, createdName=ellen0820, createdTime=Mon May 27 17:13:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=6079, encodeId=5e4a60e9f2, content=<font color=red>目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。</font> <br> ------------------------------- <br> xingxing7021于2013-8-23 16:05:00 评论道: <br> 结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=管理员, createdTime=Sat Aug 24 14:11:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6077, encodeId=175f60e778, content=结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xingxing7021, createdTime=Fri Aug 23 16:05:00 CST 2013, time=2013-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5931, encodeId=9b4a5931b1, content=很好,鼓励积极参与。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=377584482, createdName=hong0hui, createdTime=Wed Jul 17 20:59:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5748, encodeId=66cf5e4822, content=值得参加, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=88gogo, createdTime=Thu May 30 16:13:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585662, encodeId=e4ac1585662a5, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605966, encodeId=33dd16059668f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5742, encodeId=f4815e42c0, content=很好的活动,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.173.34.157, createdTime=Mon May 27 17:49:00 CST 2013, time=2013-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5741, encodeId=5f515e41a0, content=顶一个~努力赚积分!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211213/a4233b110a314856b51b2ba7363cc1a1/02edceab314e4237aec74a0678eee6bf.jpg, createdBy=507370304, createdName=ellen0820, createdTime=Mon May 27 17:13:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2013-05-27 180.173.34.157

    很好的活动,赞一个!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=6079, encodeId=5e4a60e9f2, content=<font color=red>目前一审已经结束,正在通知各位参赛成员,一审从几十份方案中入选了四份方案,作为优胜奖和优秀奖。相关结果本周会公布,并进行二审。</font> <br> ------------------------------- <br> xingxing7021于2013-8-23 16:05:00 评论道: <br> 结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=管理员, createdTime=Sat Aug 24 14:11:00 CST 2013, time=2013-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=6077, encodeId=175f60e778, content=结果在啥地方公告、?有谁看到自己申请到了吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=xingxing7021, createdTime=Fri Aug 23 16:05:00 CST 2013, time=2013-08-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5931, encodeId=9b4a5931b1, content=很好,鼓励积极参与。, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=377584482, createdName=hong0hui, createdTime=Wed Jul 17 20:59:00 CST 2013, time=2013-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5748, encodeId=66cf5e4822, content=值得参加, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=88gogo, createdTime=Thu May 30 16:13:00 CST 2013, time=2013-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585662, encodeId=e4ac1585662a5, content=<a href='/topic/show?id=921a229382d' target=_blank style='color:#2F92EE;'>#临床研究设计#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22938, encryptionId=921a229382d, topicName=临床研究设计)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e91e17265707, createdName=lishiwen, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605966, encodeId=33dd16059668f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 29 07:59:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5742, encodeId=f4815e42c0, content=很好的活动,赞一个!, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=180.173.34.157, createdTime=Mon May 27 17:49:00 CST 2013, time=2013-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=5741, encodeId=5f515e41a0, content=顶一个~努力赚积分!, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211213/a4233b110a314856b51b2ba7363cc1a1/02edceab314e4237aec74a0678eee6bf.jpg, createdBy=507370304, createdName=ellen0820, createdTime=Mon May 27 17:13:00 CST 2013, time=2013-05-27, status=1, ipAttribution=)]
    2013-05-27 ellen0820

    顶一个~努力赚积分!

    0

相关资讯

三位专家直击临床研究设计(新闻发布会)MedSci专访OCC2013:

第七届东方心脏病学会议(The 7th Oriental Congress of Cardiology,OCC 2013)于2013年5月23日在上海世博中心召开。本次会议由上海市医学会心血管病专科委员会主办,上海市十八家医院共同承办。 大会于5月23日下午15:00召开新闻发布会,MedSci就年轻医生如何进行高质量临床研究发表了提问。    MedSci通讯员

临床研究设计应遵循国际规范(附CONSORT规范和STROBE规范 中文版)

临床技能与临床研究相辅相成,从临床问题发现,到科研设计,到临床研究,再回归临床,是临床医务工作者职业发展必经之路。临床研究设计是临床研究的第一个环节,将在很大程度上影响临床研究成果的可靠性。一个优秀的临床研究,除了创新性之外,很重要的一点就是临床研究设计的规范性!临床研究的质量控制是研究的核心环节。临床研究涉及面复杂,需要尽最大可能减少或避免偏倚,呈现临床真实信息,所以临床研究的规范性至关重要。目